DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission.

Author(s): Ketter TA, Agid O, Kapur S, Loebel A, Siu CO, Romano SJ.

Affiliation(s): Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305-5723, USA. tketter@stanford.edu

Publication date & source: 2010, J Psychiatr Res. , 44(1):8-14

OBJECTIVE: To assess rapid antipsychotic efficacy with oral ziprasidone monotherapy in bipolar acute manic/mixed episodes with psychotic features, and predictive value of rapid antipsychotic response for subsequent acute manic/mixed episode remission. METHODS: Pooled analysis of two 3-week, randomized, double-blind, placebo-controlled trials of ziprasidone (40-160mg/d) in inpatients with bipolar I disorder, and a current manic or mixed episode, with (n=152) or without (n=246) psychotic features. Psychosis improvement was evaluated by change in SADS-C psychosis score (sum of delusions, hallucinations, and suspiciousness items). Rapid antipsychotic response (>or=50% decrease in SADS-C psychosis score by Day 4) and acute manic episode response and remission (endpoint >or=50% MRS decrease, and a MRS score

Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017